

Evaluation of Racial/Ethnic Differences in Treatment and Outcomes in Triple-Negative Breast Cancer

JAMA Oncology

7, 1016

DOI: [10.1001/jamaoncol.2021.1254](https://doi.org/10.1001/jamaoncol.2021.1254)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Blackâ€“White Differences in Treatment Receipt and Outcome for Triple-Negative Breast Cancer: The Competing Contributions of Access, Bias, and Biology. <i>Annals of Surgical Oncology</i> , 2021, 28, 6909-6910.	1.5	1
2	CRYÎ²B2 enhances tumorigenesis through upregulation of nucleolin in triple negative breast cancer. <i>Oncogene</i> , 2021, 40, 5752-5763.	5.9	6
3	Higher mortality risk in African American women with tripleâ€“negative breast cancer. <i>Cancer</i> , 2021, 127, 3712-3713.	4.1	0
4	A Novel Seven Gene Signature-Based Prognostic Model to Predict Distant Metastasis of Lymph Node-Negative Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 746763.	2.8	6
5	Health Disparities: Impact of Health Disparities and Treatment Decision-Making Biases on Cancer Adverse Effects Among Black Cancer Survivors. <i>Clinical Journal of Oncology Nursing</i> , 2021, 25, 17-24.	0.6	10
6	Establishment of a New Cell Line of Canine Mammary Tumor CMT-1026. <i>Frontiers in Veterinary Science</i> , 2021, 8, 744032.	2.2	4
7	Cancer statistics for African American/Black People 2022. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 202-229.	329.8	230
9	Racial and Ethnic Disparities in Synchronous and Metachronous Bilateral Breast Cancer. <i>Journal of Racial and Ethnic Health Disparities</i> , 2022, , 1.	3.2	0
10	Immune response and inflammation in cancer health disparities. <i>Trends in Cancer</i> , 2022, 8, 316-327.	7.4	21
11	Strategies to Achieve Breast Health Equity in the St. Louis Region and Beyond over 15+ Years. <i>Cancers</i> , 2022, 14, 2550.	3.7	3
12	Assessing Real-World Racial Differences Among Patients With Metastatic Triple-Negative Breast Cancer in US Community Practices. <i>Frontiers in Public Health</i> , 2022, 10, .	2.7	0
13	A Novel Risk-Scoring System to Identify the Potential Population Benefiting From Adjuvant Chemotherapy for Node-Negative TNBC Patients With Tumor Size Less Than 1 cm. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	2
14	Multiple mediation analysis of racial disparity in breast cancer survival. <i>Cancer Epidemiology</i> , 2022, 79, 102206.	1.9	4
15	Ceritinib is a novel triple negative breast cancer therapeutic agent. <i>Molecular Cancer</i> , 2022, 21, .	19.2	14
16	Treatment for Triple-Negative Breast Cancer: An Umbrella Review of Meta-Analyses. <i>International Journal of General Medicine</i> , 0, Volume 15, 5901-5914.	1.8	3
17	Primary Breast Neuroendocrine Tumors: An Analysis of the National Cancer Database. <i>Annals of Surgical Oncology</i> , 2022, 29, 6339-6346.	1.5	6
18	Impact of Marital Status on Prognosis of Patients With Invasive Breast Cancer: A Population-Based Study Using SEER Database. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	6
19	Racial and Ethnic Inequality in Survival Outcomes of Women With Triple Negative Breast Cancer. <i>Cureus</i> , 2022, , .	0.5	3

#	ARTICLE	IF	CITATIONS
20	Racial differences in anthropometric measures as risk factors for triple-negative breast cancer. <i>Cancer Causes and Control</i> , 2022, 33, 1413-1419.	1.8	2
21	Breast Cancer Statistics, 2022. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 524-541.	329.8	611
22	An SVM Based Approach to Study the Racial Disparity in Triple-Negative Breast Cancer. <i>Lecture Notes in Computer Science</i> , 2022, , 163-175.	1.3	0
23	European Cancer Organisation's Inequalities Network: Putting Cancer Inequalities on the European Policy Map. <i>JCO Global Oncology</i> , 2022, , .	1.8	6
24	Association of Race and Area Deprivation With Breast Cancer Survival Among Black and White Women in the State of Georgia. <i>JAMA Network Open</i> , 2022, 5, e2238183.	5.9	12
25	Annual report to the nation on the status of cancer, part 1: National cancer statistics. <i>Cancer</i> , 2022, 128, 4251-4284.	4.1	145
26	Breast cancer knowledge and understanding treatment rationales among diverse breast cancer survivors. <i>Breast Cancer Research and Treatment</i> , 2022, 196, 623-633.	2.5	2
27	Association between Obesity, Race or Ethnicity, and Luminal Subtypes of Breast Cancer. <i>Biomedicines</i> , 2022, 10, 2931.	3.2	6
28	Mechanisms and Strategies to Overcome PD-1/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer. <i>Cancers</i> , 2023, 15, 104.	3.7	14
29	Research Silos in Cancer Disparities: Obstacles to Improving Clinical Outcomes for Underserved Patient Populations. <i>Clinical Cancer Research</i> , 2023, 29, 1194-1199.	7.0	0
30	Ethnic disparities in the immune microenvironment of triple negative breast cancer and its role in therapeutic outcomes. <i>Cancer Reports</i> , 2023, 6, .	1.4	4
31	Examining ACCURE's Nurse Navigation Through an Antiracist Lens: Transparency and Accountability in Cancer Care. <i>Health Promotion Practice</i> , 2023, 24, 415-425.	1.6	4
32	Gaining Wings to FLY: Using <i>Drosophila</i> Oogenesis as an Entry Point for Citizen Scientists in Laboratory Research. <i>Methods in Molecular Biology</i> , 2023, , 399-444.	0.9	0
34	Identifying Biomarkers Using Support Vector Machine to Understand the Racial Disparity in Triple-Negative Breast Cancer. <i>Journal of Computational Biology</i> , 2023, 30, 502-517.	1.6	3
35	CRISPR/Cas genome editing in triple negative breast cancer: Current situation and future directions. <i>Biochemical Pharmacology</i> , 2023, 209, 115449.	4.4	3
36	Knockdown of SPON2 inhibits the growth of triple-negative breast cancer. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	4
37	Neighborhood factors and triple negative breast cancer: The role of cumulative exposure to area-level risk factors. <i>Cancer Medicine</i> , 2023, 12, 11760-11772.	2.8	3
38	Erastin plus Tubacin Treatment Promotes Breast Cancer Cell Death of HCC38. <i>Advances in Clinical Medicine</i> , 2023, 13, 8733-8740.	0.0	0

#	ARTICLE	IF	CITATIONS
39	Differences in Tumour Aggressiveness Based on Molecular Subtype and Race Measured by [18F]FDG PET Metabolic Metrics in Patients with Invasive Carcinoma of the Breast. <i>Diagnostics</i> , 2023, 13, 2059.	2.6	1
40	Addressing Inequalities in Breast Cancer Care Delivery. <i>Surgical Oncology Clinics of North America</i> , 2023, 32, 799-810.	1.5	1
41	MicroRNA Dysregulation in Early Breast Cancer Diagnosis: A Systematic Review and Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 8270.	4.1	6
42	Disparities in triple negative breast cancer. <i>Journal of the National Medical Association</i> , 2023, 115, S8-S12.	0.8	0
43	For Us, with Us: Creative Expressions as Means to Collectively Elevate Minoritized Experiences, Knowledge, and Wisdom. , 2023, , 241-269.		0
44	Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook. <i>Pharmaceutics</i> , 2023, 15, 1796.	4.5	13
45	Updates on Triple-Negative Breast Cancer in Type 2 Diabetes Mellitus Patients: From Risk Factors to Diagnosis, Biomarkers and Therapy. <i>Diagnostics</i> , 2023, 13, 2390.	2.6	3
46	Research Progress on Molecular Subtyping and Modern Treatment of Triple-Negative Breast Cancer. <i>Breast Cancer: Targets and Therapy</i> , 0, Volume 15, 647-658.	1.8	2
47	Inequities in referrals to a breast cancer risk assessment and prevention clinic: a mixed methods study. , 2023, 24, .		1
48	Environmental Justice, Equity and Cancer. , 2023, , 213-244.		0
49	VNLG-152R and its deuterated analogs potently inhibit/repress triple/quadruple negative breast cancer of diverse racial origins in vitro and in vivo by upregulating E3 Ligase Synoviolin 1 (SYVN1) and inducing proteasomal degradation of MNK1/2. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
50	Triple-Negative Breast Cancer: Histopathologic Features, Genomics, and Treatment. <i>Radiographics</i> , 2023, 43, .	3.3	2
51	Azurocidin 1 inhibits the aberrant proliferation of triple-negative breast cancer through the regulation of pyroptosis. <i>Oncology Reports</i> , 2023, 50, .	2.6	0
52	Profiling mitochondrial <scp>DNA</scp> mutations in tumors and circulating extracellular vesicles of triple-negative breast cancer patients for potential biomarker development. <i>FASEB BioAdvances</i> , 2023, 5, 412-426.	2.4	3
53	Anticancer Effects of Fucoxanthin through Cell Cycle Arrest, Apoptosis Induction, and Angiogenesis Inhibition in Triple-Negative Breast Cancer Cells. <i>Molecules</i> , 2023, 28, 6536.	3.8	2
54	Social Determinants of Cancer Disparities. <i>Annals of Surgical Oncology</i> , 0, , .	1.5	0
55	Exploring Racial Disparities in Triple-Negative Breast Cancer: Insights from Feature Selection Algorithms. <i>Lecture Notes in Computer Science</i> , 2023, , 487-497.	1.3	0
56	Deep Learning Reveals Biological Basis of Racial Disparities in Quadruple-Negative Breast Cancer. <i>Lecture Notes in Computer Science</i> , 2023, , 498-508.	1.3	0

#	ARTICLE	IF	CITATIONS
57	National trends in neoadjuvant chemotherapy utilization in patients with early-stage node-negative triple-negative breast cancer: the impact of the CREATE-X trial. <i>Breast Cancer Research and Treatment</i> , 2024, 203, 317-328.	2.5	2
58	Design of carboxymethylcellulose-conjugated polymeric prodrug micelles for enhanced in vivo performance of docetaxel. <i>International Journal of Biological Macromolecules</i> , 2023, 253, 127690.	7.5	0
59	A Public Health Emergency. <i>Obstetrics and Gynecology Clinics of North America</i> , 2024, 51, 69-103.	1.9	0
60	From Race to Racism and Disparities to Equity. <i>Cancer Journal (Sudbury, Mass)</i> , 2023, 29, 316-322.	2.0	0
61	Low Hospital Volume Is Associated with Higher All-Cause Mortality in Black Women with Triple Negative Breast Cancer. <i>Journal of Racial and Ethnic Health Disparities</i> , 0, , .	3.2	0
62	Demographic confounders distort inference of gene regulatory and gene co-expression networks in cancer. <i>Briefings in Bioinformatics</i> , 2023, 24, .	6.5	0
63	Therapeutic effect and metabolic fingerprinting of triple-negative breast cancer cells following exposure to a novel pH-responsive, gambogic acid-loaded micelle. <i>Nanotechnology</i> , 0, , .	2.6	0
64	Cost-Effectiveness of Adjuvant Olaparib for Patients With Breast Cancer and Germline <i>BRCA1/2</i> Mutations. <i>JAMA Network Open</i> , 2024, 7, e2350067.	5.9	0
65	Impact of the 2021 CKD-EPI equation on anticancer pharmacotherapy in black and non-black cancer patients. <i>Cancer Letters</i> , 2024, 586, 216679.	7.2	0
66	Lnc00113 promotes triple-negative breast cancer progression via the NOB β /MAPK signaling axis. <i>Journal of Gene Medicine</i> , 2024, 26, .	2.8	0
67	Racial/Ethnic Disparities in Pathologic Complete Response and Overall Survival in Patients With Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy. <i>Journal of Clinical Oncology</i> , 2024, 42, 1635-1645.	1.6	0
68	Racial and socioeconomic disparities in triple-negative breast cancer treatment. <i>Expert Review of Anticancer Therapy</i> , 2024, 24, 107-116.	2.4	0